Evidence map›Paper›PMID 40634095›Full record

ReviewInternal medicine (Tokyo, Japan)2026

Thyroid Storm Following Alemtuzumab-based Allogeneic Stem Cell Transplantation: A Case Report and Literature Review.

Sakura Saigusa, Kaori Uchino, Hideshige Seki, Yukie Sugita, Yuto Isaji, Yusuke Iida, Saki Shinohara, Tomohiro Horio, Satsuki Murakami, Shohei Mizuno and 8 more

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sakura SaigusaDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Kaori UchinoDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Hideshige SekiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Yukie SugitaDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Yuto IsajiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Yusuke IidaDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Saki ShinoharaDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Tomohiro HorioDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Satsuki MurakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Kazuhiro IkegameDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Ichiro HanamuraDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Junichiro MokunoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Junko TakagiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Daiki HiranoDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Japan.
Hiroatsu IidaDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Japan.
Shinji NakaoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Japan.
Akiyoshi TakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alemtuzumab-based conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) effectively reduces graft rejection but may predispose patients to autoimmune complications. We herein report a 30-year-old man with severe aplastic anemia who developed thyroid storm due to autoimmune thyroiditis 6 months after undergoing allo-HSCT with an alemtuzumab-based regimen. Despite prompt engraftment, mixed T-cell chimerism and insufficient immune regulation may have contributed to the early onset and severity of the thyroid storm. Careful monitoring of the thyroid function and immune chimerism might facilitate the early detection and management of post-transplant autoimmune complications, including thyroid storm, in patients receiving alemtuzumab-based conditioning.

Indexed as

AlemtuzumabAntineoplastic Agents, ImmunologicalHematopoietic Stem Cell TransplantationAdultAnemia, AplasticHumansMaleThyroiditis, AutoimmuneTransplantation ConditioningTransplantation, HomologousAlemtuzumabAntineoplastic Agents, Immunologicalalemtuzumabautoimmune thyroiditismixed chimerismsevere aplastic anemia

Identifiers

PMID40634095
PMCPMC12945403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.